Thera-SAbDab

ATEZOLIZUMAB

>   Structural Summary
TherapeuticAtezolizumab
TargetCD274
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK
100% seqID Fv Structure5x8l [Fvs: FK, GL, HM, JO, SN]
99% seqID Fv Structure5xxy [Fvs: HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Atezolizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 101 102 103 104 105 106 107 108 109 110 111 112 113
atezolizumab E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S D S W I H W V R Q A P G K G L E W V A W I S P Y G G S T Y Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D T A V Y Y C A R R H W P G G F D Y W G Q G T L V T V S S
5xxy E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S D S W I H W V R Q A P G K G L E W V A W I S P Y G G S T Y Y A D S V K G R F T I S A D T S K N T A Y L Q M N S L R A E D T A V Y Y C A R R H W P G G F D Y W G Q G T L V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
atezolizumab D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D V S T A V A W Y Q Q K P G K A P K L L I Y S A S F L Y S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y L Y H P A T F G Q G T K V E I K
5xxy D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q D V S T A V A W Y Q Q K P G K A P K L L I Y S A S F L Y S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q Y L Y H P A T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyHuman Phage Display
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedAmgen, ARCAGY/GINECO Group, BioLineRx, Chugai Pharmaceutical, Clovis Oncology, Dana-Farber Cancer Institute, Duke University, European Organisation for Research and Treatment of Cancer, Exelixis, Fondazione Michelangelo, GEICO (Spanish Ovarian Cancer Research Group), Genentech, GERCOR, Gradalis, H. Lee Moffitt Cancer Center and Research Institute, Immune Design, Incyte Corporation, Johns Hopkins University, Kaiser Permanente, M. D. Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, National Cancer Center (Korea), National Cancer Institute (USA), Netherlands Cancer Institute, Roche, Sanofi, Seattle Genetics, University Hospital Southampton NHS Foundation Trust, University Medical Center Groningen, University of California, University of California at San Francisco, University of Oklahoma, Yale University
Conditions ApprovedNon-small cell lung cancer, Urogenital cancer, Breast cancer, Small cell lung cancer
Conditions ActiveBladder cancer, Cervical cancer, Colorectal cancer, Fallopian tube cancer, Head and neck cancer, Liver cancer, Malignant melanoma, Ovarian cancer, Peritoneal cancer, Prostate cancer, Renal cell carcinoma, Anal cancer, Brain metastases, Chronic lymphocytic leukaemia, Cutaneous T-cell lymphoma, Diffuse large B cell lymphoma, Endometrial cancer, Gastric cancer, Gynaecological cancer, Mantle-cell lymphoma, Marginal zone B-cell lymphoma, Oesophageal cancer, Soft tissue sarcoma, Solid tumours, Thyroid cancer, Waldenstrom's macroglobulinaemia, Acute myeloid leukaemia, Follicular lymphoma, Glioblastoma, Pancreatic cancer, Haematological malignancies, Multiple myeloma, Non-Hodgkin's lymphoma
Conditions DiscontinuedHodgkin's disease, Myelodysplastic syndromes
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]